Parasitic Ulcer Treatment Trial
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Jeremy Keenan, MD, MPH
- Study ID
- NCT06213649
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Acanthamoeba Keratitis
Eligibility Criteria
- Sex
- ALL
- Age
- 8 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Polyhexamethylene biguanide (PHMB) — DRUGPHMB is a cationic antiseptic agent used for topical treatment of acanthamoeba keratitis (AK). Both treatment groups will take PHMB at least 4 times daily while on the allocated study drug.
- Topical corticosteroid — DRUGDexamethasone sodium phosphate, 0.1% ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
- Topical placebo — OTHERAn artificial tear ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
Study Details
The Parasitic Ulcer Treatment Trial (PUTT) is a multi-center, parallel-group, randomized clinical trial. The purpose of this study is to determine whether including topical corticosteroids in a regimen for acanthamoeba keratitis (AK) will improve vision. Patients presenting to all enrollment centers with evidence of acanthamoeba keratitis will be eligible for the trial if there is evidence of ocular inflammation after 4 weeks of anti-amoebic therapy. Those who agree to participate will be randomized to one of two treatment groups: * Group 1: Topical corticosteroid * Group 2: Topical placebo
Key Dates
- Start date
- Jul 1, 2024
- Status verified
- Apr 2026
- Primary completion
- Jul 31, 2029
- Completion
- Jul 31, 2029
Study Design
- Enrollment
- 232 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Topical steroidsParticipants in this arm will receive anti-amoebic therapy plus topical steroids.
- Placebo Comparator: Topical placeboParticipants in this arm will receive anti-amoebic therapy plus topical placebo.
Primary Outcome Measure
Vision [ Time Frame: 6 Months ]
Central Contacts
- Jeremy Keenan, MD, MPH415-476-6323
- Krisi Aromin
Locations (13)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94158 | Krisianne Aromin Jeremy Keenan, MD, MPH (PRINCIPAL_INVESTIGATOR) Gerami Seitzman, MD (SUB_INVESTIGATOR) |
| University of Colorado Anschutz | Aurora | Colorado | 80045 | |
| University of Florida | Gainesville | Florida | 32605 | Sonal Tuli |
| University of Miami | Miami | Florida | 33136 | Guillermo Amescua |
| University of Illinois, Chicago | Chicago | Illinois | 60612 | Elmer Tu |
| University of Iowa | Iowa City | Iowa | 52242 | Mark Greiner |
| Johns Hopkins University | Baltimore | Maryland | 21287 | Nakul Shekhawat |
| Columbia University | New York | New York | 10032 | Leejee Suh |
| Oregon Health and Science University | Portland | Oregon | 97239 | Travis Redd |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | Bennie Jeng |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15219 | |
| Baylor College of Medicine | Houston | Texas | 77030 | |
| University of Washington | Seattle | Washington | 98104 |